Proxima is a pioneering biotechnology company dedicated to revolutionizing medicine by making protein interactions programmable. By integrating advanced artificial intelligence with structural biology, Proxima aims to unlock new therapeutic possibilities through precise modulation of protein functions.
Key Features and Functionality:
- Neo-1 Model: Proxima's foundational AI model, Neo-1, unifies structure prediction and molecular design at an atomic level. It enables the design of biomolecules and accelerates structural data collection when combined with the NeoLink platform.
- NeoLink Platform: This innovative structural data generation platform utilizes cross-linking mass spectrometry (XLMS) to measure interatomic distances at scale, providing high-throughput snapshots of structural interactions.
- Integrated Discovery Platform: Proxima combines three complementary, phase-shifting technologies to fully exploit the potential of proximity modulator modalities, facilitating the development of novel therapeutics.
Primary Value and Solutions:
Proxima addresses the challenge of targeting intracellular proteins, which are often inaccessible to traditional therapies. By reprogramming existing cellular proteins and directing them toward new targets using small molecules, peptides, or macrocycles, Proxima enables the treatment of diseases previously considered untreatable. This approach opens a new chapter in medicine, offering hope for patients with limited treatment options.
